Drug Profile
Indocyanine green - Stryker Corporation
Alternative Names: IC 2000; IC2000-SPY Fluorescence Imaging Systems; IC2000-SPY-PHI; Indocyanine Green (ICG) for InjectionLatest Information Update: 03 Aug 2023
Price :
$50
*
At a glance
- Originator Novadaq Technologies
- Developer Stryker Corporation
- Class 3-ring heterocyclic compounds; Diagnostic agents; Imaging agents; Indoles; Naphthalenes; Organic sulfur compounds; Small molecules
- Mechanism of Action Diagnostic imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Breast cancer
Most Recent Events
- 28 Jul 2023 Leiden University Medical Center plans a phase II FOCUS GREEN trial for Colorectal cancer (Dignosis, Combination therapy, metastatic disease) in October 2023 (Intradermal, Injection) (NCT05965817)
- 09 Sep 2021 Chemical structure information added
- 12 Mar 2021 Phase III development in Breast cancer (Diagnosis) is still ongoing in USA (Intradermal) (NCT03200704)